Provided by Tiger Trade Technology Pte. Ltd.

Humacyte, Inc.

0.6422
-0.0392-5.75%
Post-market: 0.66490.0227+3.53%19:59 EDT
Volume:9.37M
Turnover:6.14M
Market Cap:178.53M
PE:-1.29
High:0.7000
Open:0.6741
Low:0.6345
Close:0.6814
52wk High:2.55
52wk Low:0.5261
Shares:278.00M
Float Shares:245.00M
Volume Ratio:0.56
T/O Rate:3.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4975
EPS(LYR):-0.2582
ROE:-547.87%
ROA:-49.87%
PB:5.71
PE(LYR):-2.49

Loading ...

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 24

Humacyte Inc - Enters Third Amendment to Distribution Agreement With Fresenius on April 21, 2026 - SEC Filing

THOMSON REUTERS
·
Apr 24

Humacyte Inc - Gains Sole Worldwide Rights to Distribution Product - SEC Filing

THOMSON REUTERS
·
Apr 24

Humacyte Inc - to Pay Fresenius Mid-Single to Low Double Digit Royalties on U.S. Sales - SEC Filing

THOMSON REUTERS
·
Apr 24

Humacyte regains exclusive ex-U.S. Symvess distribution rights from Fresenius Medical Care

Reuters
·
Apr 24

Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®

THOMSON REUTERS
·
Apr 24

Humacyte Inc - U.S. Distribution Terms for Symvess Remain Unchanged

THOMSON REUTERS
·
Apr 24

Humacyte Inc - Gains Exclusive Ex-U.S. Distribution Rights to Symvess; Fresenius to Receive Low-Single-Digit Royalties on Net Sales

THOMSON REUTERS
·
Apr 24

Humacyte names Jim Mercadante chief commercial officer

Reuters
·
Apr 22

Press Release: Humacyte Appoints Jim Mercadante as Chief Commercial Officer

Dow Jones
·
Apr 22

Humacyte Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Apr 21

Humacyte Says Israeli Health Ministry Accepts Marketing Authorization Application for Symvess

MT Newswires Live
·
Apr 21

Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair

THOMSON REUTERS
·
Apr 21

Humacyte: Ministry of Health Has Set 180-Working-Day Review Period for Maa Due to Existing FDA Approval of Symvess in Extremity Vascular Trauma

THOMSON REUTERS
·
Apr 21

Humacyte says Israel accepts Symvess marketing application, sets 180-day review period

Reuters
·
Apr 21

Humacyte announces annual shareholder meeting

Reuters
·
Apr 18

Humacyte Is Maintained at Overweight by Barclays

Dow Jones
·
Apr 08

Humacyte Inc. : Barclays Cuts Target Price to $1.5 From $3.5

THOMSON REUTERS
·
Apr 08

Largest borrow rate increases among liquid names

TIPRANKS
·
Apr 07

Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and Humacyte (HUMA)

TIPRANKS
·
Apr 02